n of bosentan and prostacyclin were investigated in 22 modified NYHA class III and IV PAH randomized to receive either epoprostenol and placebo or epoprostenol and bosentan (BREATHE-2).[ 73 ] There was a trend towards a greater improvement in hemodynamic parameters in the combination group but that did not reach statistical significance.
← all excerpts
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.
1
—
—